Taysha Gene Therapies, a Dallas-based biotechnology company developing novel gene therapies targeting severe and life-threatening monogenic diseases of the central nervous system (CNS), was formed on foundational science from Steven Gray, PhD and Berge Minassian, MD of the UT-Southwestern Gene Therapy Program.

Seed and Series B

Chardan’s relationships with key stakeholders and scientific expertise within in its healthcare banking platform made it uniquely positioned to advise Taysha on the roll-up of AAV gene therapy programs. Chardan advised the company on portfolio strategy and early-stage investor marketing to create an accelerated financing outreach that resonated with key investors.

After the company identified their lead seed investor, Chardan swiftly organized a roadshow to introduce the Company to new investors and shape the financing syndicate.

In addition to a successful $30 million seed round, Chardan’s marketing efforts created a foundation and level of familiarity among blue chip institutional healthcare investors. These relationships proved to be instrumental to the Company’s outreach and investor participation for its $95 million Series B prior to IPO.

IPO

Taysha priced an upsized $181 million IPO in September 2020 with Chardan acting as lead manager. Chardan’s transactional expertise from early-stage private financings through public market offerings matched the Company’s needs to accelerate to an IPO within a year of its founding.

The opportunity arose for Chardan to execute this transaction due to its extensive work in the gene therapy sector and differentiated understanding of leading academic research.